ExpansionJun 23, 2026, 09:06 AM
Myriad Genetics Expands Precise MRD™ to Breast, Colorectal, Renal Cancers
AI Summary
Myriad Genetics announced the expanded availability of its Precise MRD™ test to include breast, colorectal, and renal cancers, significantly broadening access for over 6 million individuals in the U.S. The ultrasensitive, whole-genome sequencing-based assay tracks up to 1,000 variants per patient, providing dynamic insights into disease status. This expansion is supported by the publication of results from the MONITOR-Breast study, which demonstrated the test's clinical validity and ability to predict treatment response and identify at-risk patients with high accuracy.
Key Highlights
- Precise MRD™ expanded to breast, colorectal, and renal cancers.
- Targets over 6 million U.S. individuals living with these cancers.
- Test generates personalized panel tracking up to 1,000 variants.
- MONITOR-Breast study results published in Future Oncology.
- Study evaluated 154 Stage I–III breast cancer patients.
- Precise MRD predicted pathological complete response (pCR) with 100% specificity.
- Patients ctDNA positive post-NAT were 47 times more likely to remain positive post-surgery.
- Longitudinal testing identified 44% more at-risk patients than single timepoint.
Price Impact
More from MYGN